13 stories found
Biotechnology firm Emergent BioSolutions has successfully completed the repurchase of $75 million in aggregate principal amount of its senior unsecured notes. The transaction reflects the company’s ongoing efforts to manage its debt portfolio and strengthen its balance sheet.
Emergent Biosolutions held its Q2 earnings call, providing highlights and updates on its financial performance for the quarter.
Greg Abel, CEO of Berkshire Hathaway, addressed shareholders at the company's annual meeting, reassuring them about the future in a post-Warren Buffett era. The meeting highlighted the company's record cash holdings of $397 billion and saw shareholders reject a report on workforce oversight.
Emergent BioSolutions has signed a $34.5 million deal for vaccine manufacturing and distribution.
Seeking Alpha provides a preview of Emergent Biosolutions' financial expectations ahead of its Q4 2025 earnings report.
Health organizations and companies are emphasizing opioid overdose prevention and emergency response training ahead of International Overdose Awareness Day. Experts urge the public to recognize early warning signs and act quickly to save lives.
Emergent BioSolutions' stock declined despite reporting a Q2 earnings beat, following the company's decision to cut its guidance and announce layoffs. The news impacted investor confidence.
Emergent Biosolutions has published the highlights from its first-quarter earnings call, providing insights into its recent financial results and business activities.
Emergent BioSolutions' stock experienced a significant drop following the release of its fourth-quarter results and a weak revenue guidance for 2026.
The Canadian government has awarded Emergent BioSolutions a standing supply agreement for NARCAN nasal spray to ensure consistent availability of opioid overdose reversal medication.
Emergent BioSolutions Inc. is drawing increased attention after its ACAM2000 vaccine received broader public health authorization. This development could significantly impact the company's market position.
Analysts have released their previews for the first quarter 2026 earnings reports of Emergent Biosolutions and Riot Platforms.
Emergent BioSolutions has outlined a revenue target of $720 million to $760 million for 2026, as the company continues to advance its ongoing transformation plan.